Compare FTF & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTF | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.2M | 248.8M |
| IPO Year | 2003 | 2017 |
| Metric | FTF | PROF |
|---|---|---|
| Price | $5.43 | $6.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.14 |
| AVG Volume (30 Days) | 252.8K | ★ 257.2K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | N/A | $71.10 |
| Revenue Next Year | N/A | $58.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $5.27 | $4.91 |
| 52 Week High | $6.29 | $8.95 |
| Indicator | FTF | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 52.88 | 54.06 |
| Support Level | $5.29 | $5.65 |
| Resistance Level | $5.89 | $7.04 |
| Average True Range (ATR) | 0.06 | 0.33 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 92.11 | 46.55 |
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective, is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.